Guess which ASX healthcare stock is rocketing almost 50% on Friday

This stock is avoiding the market weakness on Friday. But why?

The market may be falling today, but that hasn't stopped Biotron Ltd (ASX: BIT) shares from rocketing.

In morning trade, the ASX healthcare stock is up almost 50% to 11 cents.

A woman jumps for joy with a rocket drawn on the wall behind her.

Image source: Getty Images

Why is this ASX healthcare stock rocketing?

Investors have been scrambling to buy the antiviral therapies developer's shares this morning after it released an update on its Phase 2 study of BIT225.

BIT225 is Biotron's lead compound. It is in Phase 2 development for the treatment of HIV-1 and Hepatitis C virus infections.

According to the release, preliminary analyses of data from the BIT225-010 Phase 2 clinical trial provide confirmation, and extension, of the results of previous trials in people infected with HIV-1.

The ASX healthcare stock explained that the double-blind placebo-controlled Phase 2 trial was designed to characterise the effect of BIT225 (200 mg, once daily for 24 weeks) added to a standard of care antiretroviral therapy (cART) in 27 treatment naive people infected with HIV-1. This comprises 18 using BIT225 and 9 using a placebo.

Study participants were followed for a one-month period following 24-weeks of BIT225 or placebo dosing, with all individuals continued on cART as per standard treatment guidelines post-study.

Preliminary analysis of the safety data has shown that BIT225 was safe and generally well tolerated at the 200mg once daily dose, with no deaths or drug-related serious adverse events.

As for efficacy, preliminary analyses of the HIV-1 plasma viral load (pVL) data suggest that the addition of BIT225 to cART results in a more rapid reduction in plasma virus levels during the second phase of viral decay, compared to cART alone.

Furthermore, preliminary analyses of blood immune cell populations showed changes in specific immune cell populations in the BIT225 group compared to cART alone.

Management commentary

The ASX 200 healthcare stock's managing director, Dr Michelle Miller, was pleased with the trial results. She said:

The positive outcomes from this trial further our understanding of BIT225. The blood (plasma) viral load data in particular should be highlighted, as it suggests that BIT225 is having an impact on a critical phase of viral decay when latent reservoirs are established. Current cART is efficient at rapidly and durably reducing virus levels in the blood, but this does not translate into clearance of latent reservoirs.

The observed changes to immune markers and cells further the results from the previous 009 trial and suggest the utility of targeting viroporins as a new class of antiviral drugs. The results reported here are preliminary, and ongoing analysis of the BIT225-010 study, as well as its companion study, BIT225-011 in HIV-1 chronically infected individuals, will be reported when complete.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »